PMDA approved

Darinaparsin is a novel organic arsenical under evaluation as a cancer chemotherapeutic and has a similar structure to one of the intermediates of the arsenic detoxification pathway, and is expected to have lower toxicity than inorganic arsenic.


  • Disruption of mitochondrial functions 
  • Increase in reactive oxygen species (ROS) production
    1. Induction of apoptosis 
    2. Arrest of the cell cycle at the G2/M phase 
    3. Potent anti-angiogenesis activity


Relapse / Refractory PTCL:

  • PTCL, not otherwise specified (PTCL-NOS)
  • Angioimmunoblastic T-cell Lymphoma (AITL)
  • Anaplastic Large Cell Lymphoma (ALCL) ALK-positive/negative


For any medical enquiry, Contact us at  +91 9591736262 or Email us at info@sayretherapeutics.com